102-OR: Long-Term Kidney Outcomes following Metabolic and Bariatric Surgery in Adolescents with Severe Obesity

Introduction and Objective: Although metabolic and bariatric surgery (MBS) improves kidney function in adolescents with severe obesity up to 3 years post-surgery, long-term kidney outcomes remain unclear. This study evaluated 8-year kidney outcomes in adolescents following MBS. Methods: Data from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study, a multicenter cohort of 274 adolescents undergoing MBS, were analyzed. Urine albumin-to-creatinine ratio (ACR) and cystatin C-based estimated glomerular filtration rate (eGFR) were assessed pre- and 8 years post-surgery. Mean differences were compared via Wilcoxon signed-rank and paired t-tests (α=0.05). Results: Participants [mean preoperative age: 16.7±1.6 years; median preoperative BMI: 50.5 (45.2, 58.5) kg/m2] demonstrated significant renal improvements (Figure 1). Participants with baseline eGFR<90 mL/min per 1.73m2 (n=42) improved from 75 ± 12 to 96 ± 23 mL/min per 1.73m2 (p<0.001), while those with albuminuria (ACR≥30 mg/g, n=28) decreased from 117 (75-182) to 15 mg/g (9-24) (p<0.001). Hyperfiltration (eGFR≥135 mL/min per 1.73m2,n=24) was attenuated from 153 ± 18 to 135 ± 25 mL/min/1.73m2 (p=0.005). Conclusion: MBS in youth with severe obesity improves low eGFR and attenuates albuminuria and hyperfiltration over 8 years, highlighting its role in reducing obesity-related kidney disease and CKD risk. J.B. Rode: None. S. Jang: None. P. Bjornstad: Consultant; AstraZeneca, Bayer Pharmaceuticals, Inc, Lilly USA LLC, Novo Nordisk. A. Kula: None. T.M. Jenkins: None. S. Sisley: Consultant; Rhythm Pharmaceuticals, Inc. Research Support; Rhythm Pharmaceuticals, Inc, Eli Lilly and Company. A. Courcoulas: Research Support; Allurion, Eli Lilly and Company. M. Michalsky: Other Relationship; Intuitive Surgical, Inc. M. Helmrath: None. J.R. Ryder: Board Member; Calorify. Research Support; Boehringer-Ingelheim, Eli Lilly and Company, Recordati. T. Inge: Consultant; Mediflix, UpToDate, Teleflex, Medtronic, Eli Lilly and Company, BrainStorm Cell Therapeutics, Standard Bariatrics. Funding for Teen-LABS was provided by the National Institutes of Health (NIH) (U01DK072493 / UM1 DK072493 to T.H.I.) (UM1 DK095710 to C.X., T.M.J.) and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (8UL1TR000077). Support also came from the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, (UL1TR000114).